Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine

American Family Physician

Volumn 69, Issue 11, 2004, Pages 2619-2627

  Gahlinger, Paul M ^a,b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b Univ of Utah Health Sciences Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; COCAINE; DIAMORPHINE; FLUMAZENIL; FLUNITRAZEPAM; KETAMINE; SILDENAFIL;

AMNESIA; DEPRESSION; DIZZINESS; DRUG OVERDOSE; EUPHORIA; GENERAL PRACTICE; HUMAN; HYPERSALIVATION; HYPERTHERMIA; INTERNET; MUSCLE HYPOTONIA; PATIENT EDUCATION; PRACTICE GUIDELINE; REVIEW; SEROTONIN SYNDROME; SUBSTANCE ABUSE;

ANESTHETICS, DISSOCIATIVE; FLUNITRAZEPAM; HALLUCINOGENS; HUMANS; KETAMINE; LEISURE ACTIVITIES; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OVERDOSE; SODIUM OXYBATE; SUBSTANCE-RELATED DISORDERS;

EID: 2642533709     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Gahlinger PM. Illegal drugs: a complete guide to their history, chemistry, use and abuse. New York: Plume, 2004.
2. Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, et al. Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 2000;20:455-66.
3. Drug Abuse Warning Network. Club drugs. Rockville, Md: Office of Applied Studies, Substance Abuse and Mental Health Services Administration (SAMHSA), 2000.
4. Partnership Attitude Tracking Study Spring 2000. Teens in grades 7 through 12. Accessed March 17 2004 at: http://www.drugfreeamerica.org/acrobat/ pats2000full.pdf.
5. Koesters SC, Rogers PD, Rajasingham CR. MDMA ('ecstasy') and other 'club drugs.' The new epidemic. Pediatr Clin North Am 2002;49:415-33.
6. Fendrich M, Wislar JS, Johnson TP, Hubbell A. A contextual profile of club drug use among adults in Chicago. Addiction 2003;98:1693-1703.
7. Lenton S, Boys A, Norcross K. Raves, drugs and experience: drug use by a sample of people who attend raves in Western Australia. Addiction 1997;92:1327-37.
8. National Institute on Drug Abuse. The Monitoring the Future national results on adolescent drug use: overview of key findings, 2001. Ann Arbor, Mich: University of Michigan Institute for Social Research, 2002.
9. Graeme KA. New drugs of abuse. Emerg Med Clin North Am 2000;18:625-36.
10. Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J. Chemical analysis of ecstasy pills. JAMA 2000;284:2190.
11. National Institute on Drug Abuse. Epidemiologic trends in drug abuse: proceedings. Rockville, Md.: National Institute on Drug Abuse, Division of Epidemiology and Prevention Research, 2000.
12. Schwartz RH, Miller NS. MDMA (ecstasy) and the rave: a review. Pediatrics 1997;100:705-8.
13. Morland J. Toxicity of drug abuse-amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use. Toxicol Lett 2000;112-3:147-52.
14. Smith KM, Larive LL, Romanelli F. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm 2002;59:1067-76.
15. Olson KR, ed. Poisoning & drug overdose. 4th ed. New York: Lange Medical Books/McGraw-Hill, 2004:209.
16. Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med 2000;133:969-73.
17. Mueller PD, Korey WS. Death by "ecstasy": the serotonin syndrome? Ann Emerg Med 1998;32:377-80.
18. Inman DS, Greene D. The agony and the ecstasy: acute urinary retention after MDMA abuse. BJU Int 2003;91:123.
19. Teter CJ, Guthrie SK. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 2001;21:1486-513.
20. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine 2000;79:201-9.
21. Steele TD, McCann UD, Ricaurte GA. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction 1994;89:539-51.
22. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low-dose MDMA ("ecstasy") induces vasopressin secretion. Lancet 1998;351:1784.
23. Holmes SB, Banerjee AK, Alexander WD. Hyponatremia and seizures after ecstasy use. Postgrad Med J 1999;75:32-3.
24. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998;19:241-51.
25. Curran HV, Travill RA. Mood and cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. Addiction 1997;92:821-31.
26. Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 1998;139:261-8.
27. Ricaurte GA, McCann UD, Szabo Z, Scheffel U. Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol Lett 2000;112-113:143-6.
28. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV. 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci 2001;21:3228-35.
29. Doyon S. The many faces of ecstasy. Curr Opin Pediatr 2001;13:170-6.
30. Yates KM, O'Connor A, Horsley CA. "Herbal Ecstasy": a case series of adverse reactions. N Z Med J 2000;113:315-7.
31. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann Emerg Med 1998;31:729-36.
32. Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat 2002;23:151-6.
33. Smith KM. Drugs used in acquaintance rape. J Am Pharm Assoc 1999;39:519-25.
34. Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. MMWR Morb Mortal Wkly Rep 1990;39:861-3.
35. U.S. Drug Enforcement Administration. Gamma Hydroxybutyric Acid (GHB, liquid X, Goop, Georgia Home Boy). DEA News. March 13, 2000. Accessed March 17, 2004 at: http://www.usdoj.gov/dea/ pubs/pressrel/pr031300_01.htm.
36. Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, Lesch OM. Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol 2002;37:67-73.
37. Addolorato G, Balducci G, Capristo E, Attilia ML, Taggi F, Gasbarrini G, et al. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine. Alcohol Clin Exp Res 1999;23:1596-604.
38. Ingels M, Rangan C, Bellezzo J, Clark RF. Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med 2000;19:47-50.
39. Eckstein M, Henderson SO, DelaCruz P, Newton E. Gamma hydroxybutyrate (GHB): report of a mass intoxication and review of the literature. Prehosp Emerg Care 1999;3:357-61.
40. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992;156:380-4.
41. Garrison G, Mueller P. Clinical features and outcomes after unintentional gamma hydroxybutyrate (GHB) overdose [Abstract]. J Toxicol Clin Toxicol 1998;36:503-4.
42. Dyer JE. Gamma-hydroxybutyrate: a health-food product producing coma and seizurelike activity. Am J Emerg Med 1991;9:321-4.
43. Chin RL, Sporer KA, Cullison B, Dyer JE, Wu TD. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998;31:716-22.
44. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001;37:147-53.
45. Anglin D, Spears KL, Hutson HR. Flunitrazepam and its involvement in date or acquaintance rape. Acad Emerg Med 1997;4:323-6.
46. Schwartz RH, Weaver AB. Rohypnol, the date rape drug. Clin Pediatr 1998;37:321.
47. Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001;10:232-41.
48. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998;87:1186-93.
49. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
50. Tellier PP. Club drugs: is it all ecstasy? Pediatric Ann 2002;31:550-6.
51. Jansen KL. Non-medical use of ketamine. BMJ 1993;306:601-2.
52. Ellenhorn MJ, Barceloux DG, Ellenhorn MJ. Ellenhorn's Medical toxicology: diagnosis and treatment of human poisoning. 2d ed. Baltimore: Williams & Wilkins, 1997.
53. Dar KJ, McBrien ME. MDMA induced hyperthermia: report of a fatality and review of current therapy. Intensive Care Med 1996;22:995-6.
54. Watson JD, Ferguson C, Hinds CJ, Skinner R, Coakley JH. Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place? Anaesthesia 1993;48:1057-60.
55. Martin TG. Serotonin syndrome. Ann Emerg Med 1996;28:520-6.
56. O'Connell T, Kaye L, Plosay JJ 3d. Gamma-hydroxybutyrate (GHB): a newer drug of abuse. Am Fam Physician 2000;62:2478-83.
57. Christophersen AS. Amphetamine designer drugsan overview and epidemiology. Toxicol Lett 2000;112-113:127-31.
58. Weiner AL, Vieira L, McKay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 2000;18:447-51.